Peptides useful for inducing tolerance
CA 2132873 C · Owner: Garman, Richard D. · Inventors: Garman, Richard D.; Briner, Thomas J.; Greenstein, Julia L.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention is based on the discovery that subcutaneous administration of a peptide comprising at least one T cell epitope of a protein allergen or other protein antigen results in T cell tolerance upon subsequent exposure to the allergen or other antigen. Peptides useful for inducing tolerance in a mammal such as a , human by subcutaneous administration or other routes of administration are within the scope of this invention. Such peptides include peptide X (SEQ ID NO: 7), peptide Y (SEQ ID NO: 8), peptide Z (SEQ ID NO: 9) peptide A (SEQ ID NO: 10), peptide B , (SEQ ID NO: 11) peptide C (SEQ ID , NO: 12), peptide D (SEQ ID NO: 13) and peptide E (SEQ ID NO: 14), each as …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 25, 1993 and granted October 16, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 25, 2013.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 25, 2015.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.